IBImmunityBio IBRX · NASDAQ
$8.31 -3.82% (-$0.33)
- Market cap
- $8.92B
- Enterprise value
- $9.66B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 53.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -45.0%
- Gross margin
- 94.6%
- Net margin
- -598.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.13
- Free float
- 10.9%
About the company
ImmunityBio, Inc. (IBRX) is a biotechnology company specializing in the development of immunotherapeutic treatment therapies for various types of cancer and infectious diseases. The company is engaged in developing innovative approaches that activate patients' immune systems and help them fight diseases. ImmunityBio develops drugs that can stimulate immune response, enhance treatment efficacy, and increase the chances of successful outcomes. With the growing research in the field of immunotherapy and the need for new treatment approaches, ImmunityBio, Inc. has the potential for sustained growth. ImmunityBio, Inc. (IBRX) shares might be an interesting choice for investors seeking involvement in the biotechnology and immunotherapeutic treatment therapies industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Gerald Adcock
Employees
688
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number